Screening for neuroblastoma: 20 years and still no answer

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1530-1533

  Craft, A W ^a   Parker, L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748447719     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Miller AB. An epidemiological perspective on cancer screening. Clin Biochem 1995, 28, 41-48.
2. Wald NJ, Chamberlain ], Hackshaw A. European Society of Mastology, Consensus Conference on Breast Cancer Screening, Paris, 4-5 February 1993. Report on thé Evaluation Committee. Bull Cancer 1994, 81, 825-834.
3. Ochs J, Mulhern R. Long term sequelae of therapy for childhood acute lymphoblastic leukaemia. BaiUieres Clin Haematol 1994, 7, 365-376.
4. Evans AE, August CS, Kamani N, et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital in Philadelphia. An update. Med Pediatr Oncol 1994, 23, 323-327.
5. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factors in neuroblastoma. Cancer 1987, 59, 1853-1859.
6. Pritchard J, Barnes J, Germond S, et al. Stage and urinary catecholamine metabolite excretion in neuroblastoma. Lancet 1989, 2(8661), 514-515.
7. Tuchman M, Ramnaraine MLR, Woods WG, Krivit W. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987, 79, 203-205.
8. Sawada T, Todo S, Fujita K, Lino S, Imashuka S, Kusunoki T. Mass screening of neuroblastoma in infancy. Am J Dis Child 1982,136,710-712.
9. Sawada T. Laboratory techniques and neuroblastoma screening. Lancet 1988, 2(8620), 1134-1135.
10. Nishi M, Miyake H, Takeda T, Schimada M. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987, 60, 433-436.
11. Parker L, Craft AW, Dale G, et al. Screening for neuroblastoma in the North of England. BrMedJ 1992, 305, 1260-1263.
12. Erttman R, Schilling FH, Dohrmann S, et al. Two years experience of the German pilot study for the early detection of neuroblastoma. 3rd International Symposium on Neuroblastoma Screening. Kyoto, Japan, 1993.
13. Berthold F, Sander J, Baillot A, Hunneman DH, Michaelis J. Neuroblastomscreening-Projekt Niedersachsen/NordrheinWestfalen: Zur Notwendigkeit des Epidemiologischen Verleichs. Klin Padiatr 1992, 204, 288-292.
14. Philip TO, Mathieu P, Chauvin F, et al. A 5 year study (1990-1994) on screening babies for neuroblastoma in France. Methodological aspects and preliminary observations. 3rd International Symposium on Neuroblastoma Screening. Kyoto, Japan, 1993.
15. Kerbl R, Urban C, Starz I, et al. Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life. MedPediatr Oncol 1993, 21, 625-626.
16. Woods WG, Tuchman M, Bernstein ML, et al. Screening for neuroblastoma in North America. Am J Pediatr HematollOncol 1992,14,312-319.
17. Bayliss U, Wiley VC, Wilcken B. Neuroblastoma screening in New South Wales. 3rd International Symposium on Neuroblastoma Screening. Kyoto, Japan, 1993.
18. Craft AW, Parker L. Poor prognosis neuroblastoma: is screening the answer? BrJ Cancer 1992, 65 (Suppl), 96-101.
19. Beckwith JB, Perrin EV. In situ neuroblastomas: a contribution to the natural history of neural crest tumours. Am J Palhol 1963, 17, 1089-1104.
20. Hanawa Y, Sawada T, Tsunoda A. Decrease in childhood neuroblasoma death in Japan. Med Pediatr Oncol 1990, 18, 472-475.
21. Cole M, Parker L, Craft AW. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol. 1992, 20, 84-85.
22. Nishi M, Miyake H, Takeda T, et al. Mass screening for neuroblastoma and mortality in birth cohorts. 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany, 1995.
23. Tuchman M, Woods WG. Introduction: neuroblastoma screening. Laboratory, clinical, and epidemiological aspects. Am J Pediatr HematollOncol 1992, 14, 95-96.
24. Woods WG, Lemieux B, Leclerc JM, et al. Screening for neuroblastoma (NB) in North America: the Quebec Project. Prog Clin BiolRes 1994, 385, 377-382.
25. Woods WG, Robison LL, Tuchman M, et al. Screening for neuroblastoma (NB) increases the overall incidence of the disease without decreasing the incidence in children over 1 year of age. Presented at American Society of Pédiatrie Hematology/Oncology (ASPHO), Chicago, October 1994.
26. Tuchman M, Lemieux B, Robison LL, et al. Screening for neuroblastoma (NB) increases with overall incidence of the disease without reducing the incidence of advanced stage NB. 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany, 1995.
27. Brodeur GM, Nakagawara A. Molecular basis of heterogeneity of human neuroblastoma. EurJ Cancer 1995, 31A, 505-510.
28. Look AT, Hayes A, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a pédiatrie oncology group study. J Clin Oncol 1991, 9, 581-591.
29. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome Ip loss of heterozygosiry in neuroblastoma. Cancer Res 1995,55,4664-4669.
30. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur AM. Association between high levels of expression of the TRK gene and favourable outcome in human neuroblastoma. N Engl J Med 1993, 328, 847-853.
31. Brodeur GM, Hayes FA, Green AA, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987, 47, 44248-44253.
32. Woods WG, Tuchman M, Brodeur GM, et al. Clinical and biologic parameters from patients (PTS) diagnosed with neuroblastoma as part of the Quebec Screening Project (QNSP): differences between cases detected by screening and those diagnosed clinically. 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany, 1995.
33. Sawada T, Shikata T, Matsumuna T, Kawakatsu H, Sugimoto T. Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infant Japan. NB Screening Study Group. Prog Clin Biol Res 1994, 385, 371-375.
34. Brodeur GM, Azar C, Brother M, et al. Effect of genetic factors on prognosis and treatment. Cancer 1992, 70, 1685-1694.
35. Hayaslin Y, Ohi R. Yaoita S, et al. Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds. J Pediatr Surg 1995, 30, 467-470.
36. Parker L on behalf of the SENSE group. SENSE: Study for the Evaluation of Neuroblastoma Screening in Europe. 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany, 1995.
37. Esteve J, Parker L, et al. Is there a need for the evaluation of neuroblastoma screening: would it be feasible? BrJ Cancer 1995, 71, 1125-1131.
38. Schilling FH, Berthold F, Erttmann R, Sander J, Treuner J. An epidemiological study to evaluate neuroblastoma screening at 12 months of age in Germany. 4th International Symposium on Neuroblastoma Screening. Stuttgart, Germany, 1995.
39. Ninane J. Consensus statement of SIOP on neuroblastoma screening. SIOP Newsletter, Spring 1991.
40. Day NE. Screening for breast cancer. Br Med Bull 1991, 47, 400-415.